Aclaris Therapeutics Revenue and Competitors
Estimated Revenue & Valuation
- Aclaris Therapeutics's estimated annual revenue is currently $6.8M per year.
- Aclaris Therapeutics received $86.3M in venture funding in August 2017.
- Aclaris Therapeutics's estimated revenue per employee is $83,415
- Aclaris Therapeutics's total funding is $219.9M.
- Aclaris Therapeutics's current valuation is $661.9M. (January 2022)
Employee Data
- Aclaris Therapeutics has 82 Employees.
- Aclaris Therapeutics grew their employee count by 37% last year.
Aclaris Therapeutics Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $43.2M | 215 | 6% | N/A | N/A |
#2 | $81.8M | 407 | 10% | N/A | N/A |
#3 | $11.7M | 58 | 0% | N/A | N/A |
#4 | $1011.8M | 5034 | -9% | N/A | N/A |
#5 | $44.8M | 223 | 1% | N/A | N/A |
#6 | $13.1M | 65 | 5% | N/A | N/A |
#7 | $16.5M | 82 | 41% | N/A | N/A |
#8 | $17.3M | 86 | -5% | N/A | N/A |
#9 | $67.9M | 338 | 23% | N/A | N/A |
#10 | $14.9M | 74 | 7% | N/A | N/A |
What Is Aclaris Therapeutics?
Aclaris Therapeutics, Inc. is a dermatologist-led biopharmaceutical company committed to identifying, developing and commercializing innovative therapies to address significant unmet needs in dermatology, both medical and aesthetic, and immunology. Aclaris is focused on market segments with no FDA-approved medications or where treatment gaps exist. Aclaris was founded by dermatologists and is led by a team with extensive experience in developing and commercializing dermatologic treatments.
keywords:Biotechnology,Healthcare,Pharmaceuticals
$219.9M
Total Funding
82
Number of Employees
$6.8M
Revenue (est)
37%
Employee Growth %
$661.9M
Valuation
N/A
Accelerator
Aclaris Therapeutics's People
| Name | Title | Email/Phone |
|---|---|---|
1 | Director, Information Technology and Security | Reveal Email/Phone |
2 | Senior Director Discovery and Early Development | Reveal Email/Phone |
3 | VP Finance | Reveal Email/Phone |
4 | Senior Accounting Manager | Reveal Email/Phone |
5 | VP Clinical Development | Reveal Email/Phone |
6 | National Lead, Field Medical | Reveal Email/Phone |
7 | Sr. Director, Pharmaceutical Development | Reveal Email/Phone |
8 | VP, Scientific Affairs | Reveal Email/Phone |
9 | Senior Director, Regulatory Affairs (Consultant) | Reveal Email/Phone |
10 | Associate Director, Biologics QC | Reveal Email/Phone |
Aclaris Therapeutics News
Aclaris Therapeutics posted earnings of ($0.57) per share in the same quarter last year, which would indicate a positive year-over-year growth...
Aclaris Therapeutics, Inc. (NASDAQ:ACRS) Given Average Rating of Buy by Analysts. Posted by admin on Apr 17th, 2022.
This is a breakdown of current recommendations for NeuroSense Therapeutics and Aclaris Therapeutics, as reported by MarketBeat.com. Sell Ratings...
Aclaris Therapeutics will lay off 86 employees and end certain development programs as it restructures to extend cash for operations, the ...
Other Companies in Wayne
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
#1 | $20.8M | 82 | 11% | N/A |
#2 | $12.5M | 83 | 9% | N/A |
#3 | $16.7M | 83 | 1% | N/A |
#4 | $24.4M | 84 | 17% | N/A |
#5 | N/A | 84 | -18% | N/A |
Aclaris Therapeutics Funding
| Date | Amount | Round | Lead Investors | Reference |
|---|---|---|---|---|
| 2012-10-25 | $21.0M | A | Vivo Ventures, Fidelity Biosciences | Article |
| 2014-10-03 | $21.0M | B | Vivo Ventures | Article |
| 2015-09-11 | $10.0M | A | Switch | Article |
| 2016-06-17 | $20.0M | Undisclosed | Article | |
| 2016-11-18 | $65.0M | Undisclosed | Jefferies LLC | Article |
| 2016-11-21 | $85.2M | Undisclosed | Jefferies LLC, | Article |
| 2017-08-14 | $86.3M | Undisclosed | Jefferies LLC | Article |